Boehringer Ingelheim

C.H. Boehringer Sohn AG & Ko. is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.
History.
1885–1999.
The company supplied the most potent ingredient of Agent Orange.
2000–2016.
In 2004 the company acquired STEAG microParts GmbH. In December of the same year the company announced the acquisition of the outstanding shares of Boehringer Ingelheim Shionogi Vetmedica.
In June 2008, the company announced its intention to acquire Actimis Pharmaceuticals for $515 million, depending on the performance of Actimis' leading asthma compound AP768.
In 2009 through its US subsidiary, Boehringer Ingelheim Vetmedica Inc., acquired a significant portion of the Fort Dodge Animal Health business from Pfizer.
In 2010 BI, through its Boehringer Ingelheim Japan Investment GK subsidiary, acquired all outstanding shares of SSP CO., Ltd, with Nippon Boehringer Ingelheim Co., Ltd already holding 60.2% of SSP CO's shares.
In August 2012 the company acquired FX125L and the somatotaxin programme from Funxional Therapeutics for an undisclosed sum.
In May 2015, the company acquired the investigational drug PXS4728A from Pharmaxis’. In July, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $2.65 billion ($1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $125 million based on performance milestones. On the same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713, a third generation treatment for EGFR mutation-positive lung cancer. Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's.
The company sold the rights to Faldaprevir, a HCV protease inhibitor to Trek Therapeutics.
In July 2016 the company sold the commercialisation rights to BI 655066 (Risankizumab), to AbbVie for $595 million upfront as well as undisclosed milestone payments and royalties. BI 655066 is a drug in late-stage testing for psoriasis, and in earlier testing for Crohn's disease, psoriatic arthritis and asthma. In September of the same year the company announced it would acquire ViraTherapeutics for €210 million ($230 million), a developer of oncolytic virus therapies, dependent on the success of Phase I trials.
2016 – Sanofi asset swap.
In June 2016, the company announced it had struck an asset-swap deal with Sanofi, Boehringer would sell its consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash, whilst acquiring the Merial animal health division (valuing it at €11.4 billion / $12.4 billion). The deal could mean that Boehringer is now one of the animal healthcare global leaders. In September of the same year, Amgen announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma. As part of the asset swap, Boehringer and Merial sold a number of assets to Ceva Santé Animale - namely some animal health vaccines and pharmaceuticals from the Merial portfolio for swine, bovine and companion animals, as well as some intellectual property, manufacturing processes and R&D activities. In October 2016 the company sold its US pet vaccines business and a manufacturing plant for $885 million, to Eli Lilly Cos Elanco Animal Health division.
2018–onwards.
In April 2018 the company announced that it would launch an immuno-oncology partnership with OSE Immunotherapeutics worth up-to-$1.4 billion, focussing on developing OSE's late-preclinical-stage candidate OSE-172, a checkpoint inhibitor antibody designed to treat solid tumors. In the same month Boehringer announced a partnership with Topas Therapeutics and their virus-based vectors. In mid-September the company exercised its option to acquire viral cancer therapy developer, ViraTherapeutics, for €210 million ($245 million).
In March 2019 Boehringer announced it would acquire ICD Therapeutics. In July, subsidiary company Boehringer Ingelheim Pharmaceuticals, Inc. announced it had acquired Amal Therapeutics SA, boostings the business' focus on cancer immunotherapy and vaccine treatments.
In May 2020, the business announced it would acquire Northern Biologics Inc. which focuses on therapeutic antibodies targeting tumours. In June, the business announced it would sell off part of its stake in London-listed Hikma Pharmaceuticals (28 million out of a 40 million share holding) for around $800 million. In July, the company announced it would acquire Global Stem cell Technology, boosting its animal health business. In December, Boehringer announced it would acquire Labor Dr. Merk & Kollegen, boosting its immuno-oncology therapy range including Vesicular Stomatitis Virus and cancer vaccines platforms and Swiss-based NBE Therapeutics, adding drug candidates including a treatment being used in early trials against triple-negative breast cancer and lung cancer, for $1.5 billion.
In June 2020, Boehringer and G1 Therapeutics announced a co-promotion agreement for trilaciclib (Cosela), a CDK4/6 inhibitor designed to prevent chemotherapy-induced myelosuppression. The agreement targets small cell lung cancer, will initially run for three years, and covers the United States and Puerto Rico.
Business overview.
Boehringer Ingelheim works in human pharmaceuticals, animal health, and biopharmaceuticals. The group consists of 145 affiliated companies with around 50,000 employees in 2017 in all continents. Research and development facilities were in five sites and 20 production plants in 13 countries. The research and development facilities are located in Biberach (Germany), Ridgefield (Connecticut), Vienna, Kobe, and Milan (closed in 2017). Over 8,000 employees work for Boehringer Ingelheim in research and development.
Operational sites.
Boehringer Ingelheim is a globally operating company, with 146 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.
Closure of Bedford plant.
In 2011 Ben Venue Laboratories in Bedford, Ohio, a division of Boehringer Ingelheim, voluntarily shut down after a U.S. Food and Drug Administration inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid', later found to be urine. The company invested to upgrade the drug manufacturing plant, and limited production resumed in October 2012. However, on 3 October 2013, Ben Venue announced that it would be ceasing production by the end of 2013 due to being unable to "return to sustainable production."
Collaborative research.
Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.
Products.
Key lines.
Prescription Medicines:
Consumer Health Care (sold to Sanofi):
Animal Health: 
Product pipeline.
Boehringer Ingelheim's product pipeline targets lung disease, cancer, and hepatitis C.
Litigation.
In October 2012 Boehringer Ingelheim settled a "qui tam" (whistleblower) case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.
In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On 28 May 2014, a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug.
In popular culture.
The company is mentioned as being a former place of work for one of the characters in season two, episode ten, of the Scandinavian police thriller series, "The Bridge" (Danish/Swedish TV series).
Ownership and leadership.
As a private company, Boehringer Ingelheim (BI) is not required to disclose detailed financial information publicly; the owners have considered an IPO and ruled it out. In 2006, the Chairman of the Shareholders’ Committee Dr Heribert Johann retired and Christian Boehringer took over the position as chairperson of the board of directors. As of 2018 Christian Boehringer remains in this position. In 2015, then-CFO Hubertus von Baumbach took over the position of Chairman of the Board of Managing Directors, a CEO position, to replace Andreas Barner who took the position in 2009.